Edition:
India

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

30.54USD
24 Nov 2017
Change (% chg)

$0.40 (+1.33%)
Prev Close
$30.14
Open
$30.16
Day's High
$30.89
Day's Low
$30.00
Volume
79,607
Avg. Vol
343,870
52-wk High
$32.84
52-wk Low
$11.49

Select another date:

Thu, Nov 2 2017

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update

BRIEF-Arsanis appoints Michael Gray as chief financial officer

* Arsanis announces appointments of Chip Clark and David Mcgirr to board of directors and promotion of Michael Gray to chief operating officer and chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Insmed announces proposed public offering of common stock

* Insmed Inc - ‍Has commenced an underwritten public offering of $250 million of shares of its common stock​

Insmed shares skyrocket after lung drug meets key study's main goal

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

Insmed shares skyrocket after lung drug meets key study's main goal

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

BRIEF-Insmed announces positive top-line results from phase 3 convert study of ALIS

* Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)

BRIEF-Insmed reports Q2 loss per share $0.72

* Insmed reports second quarter 2017 financial results and provides business update

Select another date: